NCT03094169 - AVID100 in Advanced Epithelial Carcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

November 28, 2020

Study Completion Date

January 30, 2021

Conditions

Solid Tumor, AdultTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaNon Small Cell Lung Cancer

Interventions

DRUG

AVID100 IV

AVID100 is administered once every 3 weeks

Trial Locations (10)

The Tisch Cancer Institute-Mt. Sinai, New York

Fox Chase, Philadelphia

START Midwest, Grand Rapids

Texas Oncology-Baylor -Charles A. Sammons Cancer Center, Dallas

University of Texas Southwestern Medical Center, Dallas

Texas Oncology Tyler, Tyler

Texas Oncology NE San Antonio, San Antonio

Texas Oncology McAllen, McAllen

Texas Oncology Midtown, Austin

Yale, New Haven